Luiz Belardinelli

Chief Tech/Sci/R&D Officer at InCarda Therapeutics, Inc.

Health Technology

Profile

Luiz Belardinelli is currently the Chief Medical Officer at InCarda Therapeutics, Inc. He previously worked as the Senior Vice President-Pharmacology at CV Therapeutics, Inc.

Luiz Belardinelli active positions

Companies	Position	Start
InCarda Therapeutics, Inc. InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.	Chief Tech/Sci/R&D Officer	05/04/2016

All active positions of Luiz Belardinelli

Former positions of Luiz Belardinelli

Companies	Position	End
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Corporate Officer/Principal	02/05/2011

See the detail of Luiz Belardinelli's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Luiz Belardinelli's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Health Technology
InCarda Therapeutics, Inc. InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.	Health Technology